Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Nov 17, 2017)
  • 8-K (Oct 26, 2017)
  • 8-K (Oct 11, 2017)
  • 8-K (Aug 7, 2017)
  • 8-K (Jul 27, 2017)
  • 8-K (May 11, 2017)

 
Other

Boston Scientific 8-K 2007

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Graphic
  4. Graphic
Unassociated Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549
 

 
FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 

 
Date of Report (Date of earliest event reported):     March 12, 2007

 
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)

DELAWARE
1-11083
04-2695240
(State or other
(Commission
(IRS employer
jurisdiction of
file number)
identification no.)
incorporation)
   

One Boston Scientific Place, Natick, Massachusetts
01760-1537
(Address of principal executive offices)
(Zip code)

Registrant’s telephone number, including area code:  (508) 650-8000
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 

ITEM 8.01.
OTHER EVENTS.
 
On March 12, 2007, Boston Scientific Corporation (the Company) issued a press release announcing that the Company’s Board of Directors has authorized management to explore an initial public offering (IPO) of a minority interest in its Endosurgery group. An IPO would involve Boston Scientific selling approximately 20 percent of the Endosurgery group and establishing a separately traded public company. The new company would remain a majority-owned subsidiary of Boston Scientific.  The press release is attached hereto as Exhibit 99.1.
 



ITEM 9.01.
FINANCIAL STATEMENTS AND EXHIBITS.
 
99.1            Press Release issued by Boston Scientific Corporation dated March 12, 2007.

 
 
 
 
 
 
 
 
 


 
 

 
SIGNATURE


Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
     
  BOSTON SCIENTIFIC CORPORATION
 
 
 
 
 
 
Date:       March 12, 2007 By:   /s/ Lawrence J. Knopf
 
Lawrence J. Knopf
 
Vice President and Assistant General Counsel
 
 

 

 
 
 
 
 
 
 
 
 
 

 
 
 

 
INDEX TO EXHIBITS


Exhibit
Number
Description

99.1
Press Release dated March 12, 2007.
 
 
 
 
 

 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki